PSMA-REACH: Real-world effectiveness and treatment patterns of [ 177 Lu]Lu-PSMA-617 in patients with mCRPC (EANM 2026) - Sep 29, 2026 - Abstract #OP-457; Pres time: Oct 19, 2026; 03:00 PM - 04:30 PM; Location: Hall G1; "Aim/Introduction: The Phase3 VISION randomized controlled trial has demonstrated the efficacy and safety of [177Lu]Lu-PSMA-617 in patients who have metastatic Castration-Resistant Prostate Cancer (mCRPC) pretreated with docetaxel (1)...Among the 203 patients with a next treatment, 44.3% received Cabazitaxel after [177Lu]Lu-PSMA-617... In routine clinical practice [177Lu] Lu-PSMA-617 demonstrated clinically meaningful overall survival with no new safety signal in a heavily pretreated mCRPC population."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
F. Courbon 1; C. Bailly 2; A. Flechon 3; A. Giraudet 3; P. Blanchard 4; G. Fiard 5; M. Pouriel 6; E. Duperray 6; P. Barthelemy 7; G. Roubaud 8
|